Market News & Trends
ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer RNA Editing Program Targeting NTCP for Cholestatic Diseases
ProQR Therapeutics NV recently announced new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical proof of concept data for…
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
Therini Bio, Inc. recently announced positive preclinical data supporting the development of its lead candidate, THN391, for the treatment of neurodegenerative ocular diseases. The data…
FDA Grants Orphan Drug Designation to Biompharma’s Microbiome-Modifying Biologic
BIOM Pharmaceutical Corporation recently announced Bi104, its innovative drug product, has been granted orphan-drug designation by the US FDA for the treatment of Angelman syndrome…
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Etedesiran for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001), the company's lead clinical development program, for…
Derm-Biome Pharmaceuticals & TransBIOtech Awarded $450,000 Applied Research & Development Grant
Derm-Biome Pharmaceuticals, Inc. recently announced that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and…
Eledon Announces Clinical Progress With Tegoprubart in the Prevention of Transplant Rejection
Eledon Pharmaceuticals, Inc. recently announced the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a…
MannKind Receives FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial Lung Disease
MannKind Corporation recently announced the US FDA has granted Fast Track designation of Clofazimine Inhalation Suspension (MNKD-101) for the treatment of nontuberculous mycobacterial (NTM) lung…
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
Lantern Pharma Inc. recently announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics, to optimize the development of its first-in-class protein disulfide isomerase (PDI) inhibitor drug…
EyeDNA Therapeutics Announces Positive 24-month Data From Ongoing Phase 1/2 Trial of HORA-PDE6b Gene Therapy in Patients With Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
eyeDNA Therapeutics recently announced positive 24-month follow-up results from its Phase 1/2 study (NCT03328130) evaluating the safety and efficacy of HORA-PDE6b, its investigational gene therapy…
Enable Injections Expands Strategic Partnership With Roche
Enable Injections, Inc. recently announced it has expanded its partnership with Roche through a collaboration, allowing Roche to develop and apply Enable’s expertise….
DevPro Biopharma & Bespak Complete Early Feasibility Studies for New Groundbreaking Albuterol Inhaler
DevPro Biopharma and Bespak have recently announced the completion of early feasibility studies on DP007, a new formulation of albuterol in a pressurized metered dose….
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicines
Creyon Bio, Inc. recently announced encouraging clinical data highlighting the use of its custom designed data set paired with artificial intelligence (AI) to rapidly engineer…
Inmagene Announces Completion of Enrollment in Phase 2a Trial of a Nondepleting & Half-Life Extended Anti-OX40 Monoclonal Antibody
Inmagene Biopharmaceuticals recently announced it completed target enrollment in its Phase 2a trial evaluating IMG-007 in adult patients with AA. IMG-007 is a nondepleting anti-OX40…
Bespak & H&T Presspart Enter Collaboration Agreement to Advance Transition to Low GWP Propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programs with low GWP propellants….
Bespak & Medicines Evaluation Unit Collaborate to Accelerate Clinical Trials on Climate-Friendly Inhalers
Bespak and The Medicines Evaluation Unit (MEU) recently announced a collaboration to further accelerate the pharmaceutical industry’s transition from existing pressurized Metered Dose Inhaler (pMDI)…
PCI Pharma Services Begins Installation of Sterile Fill-Finish & Lyophilization Line as Part of $100-M New Facility Expansion
PCI Pharma Services has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus. Twin lyophilizers and a state-of-the-art large-scale isolator….
Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1….
Guangzhou Bio-gene Technologies Announces Initiation of Phase 1 Clinical Trial for CAR-T Targeting CLL-1
Guangzhou Bio-gene Technologies recently announced the first patient was treated with BG1805, an investigational autologous CAR-T cell therapy targeting CLL-1, a member of the C-type…
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit & Achieves Significant Milestone With Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Allarity Therapeutics, Inc. recently announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced…
Pluri Launches Novel Immunotherapy Platform for Solid Tumor Treatment
Pluri Inc. recently launched its placental allogeneic MAIT cell platform for immunotherapy treatment for solid tumors – a significant medical need which currently lacks effective…
